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ABSTRACT
Objectives: The effect of antiviral therapy on clinical
outcomes in chronic hepatitis B virus (HBV) is not
established. We aimed to assess the effects of interferon
and/or nucleos(t)ide analogues versus placebo or no
intervention on prevention of hepatocellular carcinoma
(HCC) and mortality in chronic HBV.
Design: Random-effects pairwise meta-analysis of
randomised trials and observational studies.
Setting: Electronic and manual searches were
combined. Randomised controlled trials (RCTs) were
included in the primary analyses. Observational studies
were included in sensitivity analyses.
Primary and secondary outcome measures: The
primary outcome measures were HCC incidence and
mortality. The secondary outcome measure was HCC
mortality.
Results:We included 8 RCTs, 8 prospective cohort
studies and 19 case–control studies with a total of 3433
patients allocated to antiviral therapy and 4625 controls.
The maximum duration of follow-up was 23 years.
Randomised trials found no effect of antiviral therapy on
HCC or mortality. Cohort studies found that antiviral
therapy increased the risk of HCC (risk ratio 1.43; 95% CI
1.06 to 1.95), whereas case–control studies found a
decreased risk of HCC in the intervention group (risk ratio
0.69; 95% CI 0.54 to 0.88). There was a clear difference
between the results of RCTs and observational studies
(test for subgroup differences, p<0.001). Antiviral therapy
did not affect mortality in cohort studies, but reduced
mortality in case–control studies (relative risk 0.71; 95%
CI 0.54 to 0.93; test for subgroup differences, p=0.406).
Conclusions: The effect of antiviral therapy on clinical
outcomes in HBV remains to be established. Although
there was a positive effect in the sensitivity analyses, the
strength of the evidence does not allow for extrapolation
to clinical practice as research design plays an essential
role in the overall assessment.
Trial registration number: Prospero number
CRD42013003881.
INTRODUCTION
Worldwide, two billion people have been
infected with hepatitis B virus (HBV).
Chronic HBV may lead to hepatocellular car-
cinoma (HCC), cirrhosis and liver failure,
and each year about 600 000 people die due
to hepatitis.1–3 Globally, HCC is the ﬁfth
most common cause of cancer deaths in
men, and the sixth in women.4–6 Vaccine
programmes have decreased the incidence of
HBV,7 8 but mortality from HBV-related HCC
and cirrhosis is increasing due to the high
prevalence of chronically infected
patients.9 10 The aim of antiviral treatment is
to prevent progression to these clinical
outcome measures.11–13 Recommended treat-
ments include interferon and nucleos(t)ide
analogues (NA).14 15 A viral response may
reduce the risk of HCC,12 but the results of
clinical studies and meta-analyses on antiviral
ARTICLE SUMMARY
Article focus
▪ The effect of antiviral treatment for chronic hepa-
titis B has been assessed using surrogate
markers.
▪ An evaluation of the effect on hepatocellular car-
cinoma and mortality is missing.
Key messages
▪ Research design plays an essential role on the
hepatocellular carcinoma incidence estimates. As
prospective cohorts and case–control series
show opposing results, the reports from such
trials should be interpreted with caution.
▪ Sensitivity analyses show a positive effect of
treatment on mortality.
Strengths and limitations of this study
▪ A large number of observational studies were
included that allowed for detailed sensitivity ana-
lyses with tests for subgroup differences.
▪ Only eight randomised controlled trials were
included.
▪ The effect of modern nucleos(t)ides could not be
assessed as newer trials do not include placebo-
treated or untreated patients in the control
groups.
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therapy are not consistent.16–24 One meta-analysis25
found that antiviral therapy decreased liver-related mor-
tality, whereas a cohort series found decreased overall
mortality in patients with a viral response to interferon.26
On the other hand, randomised controlled trials (RCTs)
have failed to show an effect on HCC or mortality.27 28 We
therefore conducted a systematic review of the evidence
on antiviral treatment for prevention of HCC and mortal-
ity in patients with HBV.
METHODS
Scope
This systematic review evaluates the effects of antiviral
therapy versus placebo or no intervention on prevention
of HCC and mortality in patients with HBV. The review
is based on a registered written protocol (Prospero
number CRD42013003881) according to the methods
speciﬁed in the Cochrane Handbook for Reviews on
Interventions29 and the MOOSE Guidelines for
Meta-Analyses and Systematic Reviews of Observational
Studies.30 For a more detailed description of the
methods, please see the MOOSE checklist.
Data sources
Eligible trials were identiﬁed through electronic and
manual searches. Electronic searches were performed in
MEDLINE (1966–2012), EMBASE (1928–2012) and Web
of Science (1900–2012). Literature searches included
keywords for HCC, chronic HBV and antiviral treatment.
Manual searches included scanning of reference lists in
relevant papers and conference proceedings and the
International Clinical Trials Registry Platform.
Study selection
Our primary analyses included RCTs (primary analyses)
on antiviral interventions (interferon and/or NA) versus
placebo or no intervention for patients with HBV who
had not previously received antiviral therapy (treatment
naïve). Owing to the expected prognosis and the dur-
ation of follow-up necessary to evaluate intervention
effects on clinical outcome measures in HBV, observa-
tional studies were included in sensitivity analyses. The
primary outcome measures were HCC diagnosed using
recommended criteria31 32 and all-cause mortality. To
avoid prevalent cases of HCC, the outcomes were
assessed after at least 12 months of follow-up. Some
studies did not perform screening ultrasonography and
would therefore not detect small HCC present at inclu-
sion. Hence, 12 months was chosen as a limit. The sec-
ondary outcome measure was HCC-related mortality.
Data extraction and quality assessment
Two authors extracted data independently. When data
were not available in the published reports, additional
information was retrieved through correspondence with
the primary investigators.
The Cochrane Collaboration’s Tool for Assessing Risk
of Bias was used to evaluate bias control in RCTs. The
assessment included the randomisation methods (alloca-
tion sequence generation and allocation concealment),
blinding (of participants, personnel and investigators),
completeness of outcome data, reporting of data and
other biases.33 All observational studies were classed as
having a high risk of bias. Based on the MOOSE
guidelines, the assessment of potential sources of bias
within observational studies included documentation of
how data were classiﬁed and coded (multiple raters,
blinding and inter-rater reliability), assessment of con-
founding (comparability of cases and controls in studies
where appropriate) and blinding of quality assessors,
stratiﬁcation or regression on possible predictors of
study results.
Data synthesis and analysis
Statistics were performed using Stata V.12 (Statacorp,
College Station, Texas, USA) and Trial Sequential
Analysis (CTU, Copenhagen, Denmark). Meta-analyses
were performed with results expressed as risk ratios,
95% CI and I2 as a marker of heterogeneity. For
meta-analyses showing a statistically signiﬁcant effect, the
number needed to treat was calculated based on the risk
difference. Initial sensitivity analyses included repeating
all meta-analyses using both random and ﬁxed effect
models. The results of these analyses were only reported
if the conclusions differed. Regression analyses were per-
formed to assess for publication bias and other small-
study effects (Egger’s test). Sequential analyses were per-
formed for meta-analyses showing an intervention effect
after adjusting for the risk of bias associated with cumu-
lative testing.34 The sequential analysis was performed
using a random effects model, α (5%), power (80%)
and the incidence rates and the intervention effects
identiﬁed in the meta-analyses. Preplanned sensitivity
analyses were performed with the inclusion of observa-
tional studies. These analyses were performed stratiﬁed
by study design (RCT, prospective cohort or case–
control study) and with ﬁxed-effect inverse variance
models that compared the results of subgroups.
The result of the subgroup comparisons was expressed
as p values (test for subgroup differences). Additional
sensitivity analyses were performed to evaluate the inﬂu-
ence of bias control (limiting the analysis to trials with
adequate randomisation), the type of antiviral therapy
(comparing interferon, NA or both) and the effect of
HCC screening (comparing the results of trials with or
without screening). Finally, subgroup analyses including
only patients with cirrhosis were performed.
RESULTS
Literature searches and study inclusion
The electronic and manual searches identiﬁed 27 474
potentially relevant records (ﬁgure 1). After excluding
duplicates and studies that did not fulﬁl our inclusion
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criteria, 36 references referring to 8 RCTs, 8 prospective
cohort studies and 19 case–control studies were
included.26–28 35–67
Characteristics of the included RCTs and observational
studies
The RCTs were conducted in Europe (n=4), Asia (n=2)
and Africa (n=2). The duration of follow-up ranged from
1 to 11 years. One trial performed HCC screening. Six
trials assessed interferon and two trials focused on NA
(table 1). A total of 840 patients received antiviral
therapy and 447 patients received placebo or no interven-
tion. The proportion of men ranged from 70% to 100%
and the mean age ranged from 33 to 44 years. The pro-
portion of patients with cirrhosis at inclusion ranged
from 0% to 66% (table 2). The proportion of patients
with a virological response ranged from 7% to 58% in the
treatment group and from 1% to 22% in controls. A bio-
chemical response was achieved in 14–66% of patients in
the treatment group and in 1–20% of controls. The ran-
domisation methods were described as adequate in three
trials (table 3).
The prospective cohorts and case–control studies were
conducted in Europe (n=12), Asia (n=13), North
America (n=1) and South America (n=1). The duration
of follow-up ranged from 2 to 23 years. HCC screening
was performed in all prospective cohort studies and in
13 of the case–control studies. In total, 18 studies
assessed interferon, 7 assessed NA and 2 combined
therapy with interferon and NA (table 1). A total of
2593 patients received antiviral therapy and 4178
patients received no intervention. The proportion of
men ranged from 53% to 95% and the mean age
ranged from 27 to 65 years. The proportion of patients
with cirrhosis ranged from 0% to 100% (table 2). In the
prospective cohorts, the proportion of patients with a
virological response in the treatment and control groups
was 23–69% and 0–23%, respectively. A biochemical
Figure 1 Flow diagram of the study.
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Table 1 Characteristics of trials
Study, year (reference)
Country of
origin Intervention (dose)
Number of
patients
Follow-up (mean/
median year)
HCC screening
(yes/no) Outcomes reported
Randomised controlled trials
Anderson et al, 198735 England IFN (2.5–7.5 MU/m2/d) I 14
C 16
I 1.0
C 1.0
No Overall mortality
Chan et al, 200739 China Lamivudine (100 mg/d) I 89
C 47
I 2.5
C 2.5
No HCC incidence
Farci et al, 200443 Italy IFN (3–9 MU/×3w) I 28
C 10
I 10.8
C 10.8
No Overall mortality
Krogsgaard, 199828 Europe IFN (1.5–18 MU/×3w) I 210
C 98
I 1.3
C 1.3
No HCC incidence and
mortality
Liaw et al, 200427 Asia Lamivudine (100 mg/d) I 436
C 215
I 2.7
C 2.7
Yes HCC incidence
Overall mortality
Mazzella et al, 199953 Italy IFN (648 MU total) I 33
C 31
I 7.2
C 6.6
No HCC incidence and
mortality
Robson et al, 199256 South Africa IFN (10 MU/×3w) I 10
C 10
I 1.4
C 1.4
No Overall and HCC mortality
Waked et al, 199062 Egypt IFN (5 MU/m2/×3w–
5 MU/m2/d)
I 20
C 20
I 1.3
C 1.3
No Overall and HCC mortality
Prospective cohorts
Benvegnu et al, 199836 Italy IFN (5–10 MU/×3w) I 13
C 24
I 6.0
C 6.0
Yes HCC incidence
Overall mortality
Brunetto et al, 200238 Italy IFN (9 MU/×3w) I 103
C 61
I 6.0
C 6.0
Yes Overall mortality
Chan et al, 201240
Wong et al, 201063
China Nucleos(t)ides IFN
(NS)
I 158
C 1271
I 10.1
C 10.1
Yes HCC incidence, overall and
HCC mortality
Di Marco et al, 199942 Italy IFN (NS) I 109
C 193
I 7.8
C 7.8
Yes Overall mortality
Ma et al, 200849 China Nucleos(t)ides (NS) I 41
C 176
I 2.9
C 2.9
Yes Overall mortality
Mazzella et al, 199652 Italy IFN (10 MU/×3w) I 34
C 28
I 4.1
C 4.0
Yes HCC incidence
Papatheodoridis et al, 200155 Greece IFN (3 MU/×3w) I 209
C 152
I 6.0
C 6.1
Yes HCC incidence, overall and
HCC mortality
Tong et al, 200659 USA IFN (NS) I 22
C 378
I 7.0
C 7.0
Yes HCC incidence, overall and
HCC mortality
Case–control series
Bolukbas et al, 200637 Turkey Lamivudine (100 mg/d) I 23
C 15
I 1.5
C 2.0
Yes Overall and HCC mortality
Das et al, 201041 India Lamivudine Adefovir
(NS)
I 151
C 102
I 4.0
C 3.8
Yes HCC incidence, overall and
HCC mortality
Fattovich et al, 199744 Europe IFN (36 MU to
>300 MU total)
I 40
C 50
I 6.2
C 6.2
No HCC incidence, overall and
HCC mortality
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Table 1 Continued
Study, year (reference)
Country of
origin Intervention (dose)
Number of
patients
Follow-up (mean/
median year)
HCC screening
(yes/no) Outcomes reported
IIHCSG, 199845 Italy and
Argentina
IFN (9 MU/w) I 49
C 97
I 5.8
C 6.9
Yes HCC incidence
Ikeda et al, 199846 Japan IFN (6 MU/×2w) I 94
C 219
I 6.8
C 7.0
Yes HCC incidence
Lin et al, 200147 China IFN (5 MU/×3w) I 30
C 28
I 2.7
C 2.6
No HCC incidence, overall and
HCC mortality
Lin et al, 200748 China IFN (6–9 MU/m2/×3w) I 233
C 233
I 6.8
C 6.1
Yes HCC incidence and
mortality
Mahmood et al, 200550 Japan IFN (6 MU/d) I 23
C 68
I 7.0
C 7.0
Yes HCC incidence
Manolakopoulos et al, 200426 Greece Lamivudine (100 mg/d) I 30
C 30
I 1.5
C 1.8
Yes HCC incidence, overall and
HCC mortality
Matsumoto et al, 200551 Japan Lamivudine (100 mg/d) I 508
C 231
I 2.7
C 5.3
No HCC incidence
Niederau et al, 199654 Germany IFN (2–5 MU/×3w) I 103
C 53
I 4.2
C 3.2
No Overall mortality
Romeo et al, 200957 Italy Lamivudine (NS)
IFN (6–9 MU)
I 102
C 135
I 22.4
C 16.5
Yes HCC incidence, overall and
HCC mortality
Tangkijvanich et al, 200158 Thailand IFN (3–6 MU/×3w) I 67
C 72
I 4.9
C 4.9
Yes HCC incidence
Tong et al, 200960 USA Lamivudine (NS) I 27
C 101
I 5.3
C 5.3
Yes HCC incidence and
mortality
Truong et al, 200561 Japan IFN (174–687 MU
total)
I 27
C 35
I 7.0
C 6.2
Yes HCC incidence and
mortality
Yuen et al, 200164 China IFN (2.5–10 MU/m2/
×3w)
I 208
C 203
I 8.9
C 9.0
Yes HCC incidence and
mortality
Yuen et al, 200465 China IFN (NS) I 6
C 86
I 10.5
C 10.5
No HCC incidence
Yuen et al, 200766 China Lamivudine (100 mg/d) I 142
C 124
I 7.5
C 9.0
Yes HCC incidence
Zampino et al, 200967 Italy IFN (5 MU/m2/×3w) I 41
C 13
I 23
C 23
No HCC incidence
/d, Daily; /×3w, thrice weekly; C, control; HCC, hepatocellular carcinoma; I, intervention; IFN, interferon; MU, million units; NS, not stated.
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Table 2 Patient characteristics in included trials
Study, year (reference)
Median/mean
age (years)
Proportion of
men (%)
Proportion with
cirrhosis (%)
Proportion with
elevated ALT (%)
Proportion positive
for HBeAg (%)
HBeAg
seroconverters (n, %)
Randomised controlled trials
Anderson et al, 198735 I 36
C 35
100 20 77 100 I 2, 14
C 0, 0
Chan et al, 200739 I 39
C 39
84 16 77 5 NS
Farci et al, 200443 I 35
C 38
83 66 100 2 I NA
C 1, 100
Krogsgaard, 199828 I 36
C 36
81 19 100 100 NS
Liaw et al, 200427 I 43
C 44
85 33 78 58 NS
Mazzella et al, 199953 I 36
C 41
78 0 100 100 I 30, 91
C 19, 61
Robson et al, 199256 I 33
C 31
70 NS 100 100 I 5, 50
C 1, 10
Waked et al, 199062 I 35
C 35
78 40 100 100 I 13, 81
C 5, 33
Prospective cohorts
Benvegnu et al, 199836 I 57
C 60
65 100 NS NS NS
Brunetto et al, 200238 I 40
C 40
80 38 NS 0 NA
Chan et al, 201240
Wong et al, 201063
NS 67 32 87 NS NS
Di Marco et al, 199942 I 33
C 35
71 29 100 29 I 35, 32
C 29, 15
Ma et al, 200849 I 54
C 54
72 100 NS 24 NS
Mazzella et al, 199652 I 48
C 49
73 100 NS NS NS
Papatheodoridis et al, 200155 I 47
C 49
83 31 100 0 NA
Tong et al, 200659 I 48
C 48
71 35 NS 49 NS
Case–control series
Bolukbas et al, 200637 I 45
C 46
82 100 NS 0 NA
Das et al, 201041 I 42
C 46
91 100 NS 45 I 12, 13
C 3, 10
Fattovich et al, 199744 I 47
C 45
87 100 100 100 I 27, 68
C 30, 60
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Table 2 Continued
Study, year (reference)
Median/mean
age (years)
Proportion of
men (%)
Proportion with
cirrhosis (%)
Proportion with
elevated ALT (%)
Proportion positive
for HBeAg (%)
HBeAg
seroconverters (n, %)
IIHCSG, 199845 I 54
C 54
64 100 NS NS NS
Ikeda et al, 199846 I 41
C 44
79 100 NS 52 NS
Lin et al, 200147 I 39
C 41
95 10 100 0 NA
Lin et al, 200748 I 32
C 31
94 9 NS 100 I 115, 49
C 86, 37
Mahmood et al, 200550 I 49
C 49
69 100 NS 36 NS
Manolakopoulos et al, 200426 I 65
C 63
80 100 100 0 NA
Matsumoto et al, 200551 I 42
C 41
73 18 NS 55 NS
Niederau et al, 199654 I 40
C 41
78 28 100 100 I 53, 51
C 7, 13
Romeo et al, 200957 NS 77 35 NS 27 NS
Tangkijvanich et al, 200158 I 37
C 40
72 20 NS 100 I 24, 36
C 7, 10
Tong et al, 200960 I 46
C 46
86 100 14 53 NS
Truong et al, 200561 I 33
C 37
53 2 100 60 I 9, 53
C 11, 55
Yuen et al, 200164 I 27
C 28
64 NS 32 100 I 96, 46
C 93, 46
Yuen et al, 200465 I 43
C 43
71 NS NS 23 NS
Yuen et al, 200766 I 34
C 33
74 0 48 100 NS
Zampino et al, 200967 NS 67 0 NS 54 I 16, 62
C NS
ALT, alanine aminotransferase; C, Control; HBeAg, hepatitis B e antigen I, Intervention; NA, not applicable; NS, not stated;.
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response was achieved for 23–69% of patients in the
treatment groups and 31% in the control group (only
reported in 1 study). In the case–control series, the pro-
portion of patients with a virological response in the
treatment and control groups ranged from 7% to 78%
and 2% to 100%, respectively. A biochemical response
in the two groups was 27–68% and 4–51%, respectively.
Prevention of HCC
HCC was diagnosed in 22 of 768 patients in the treat-
ment group versus 19 of 391 controls (relative risk 0.58,
95% CI 0.32 to 1.07; I2=0%). There was no evidence of
small-study effects (Egger’s test, p=0.269) and no differ-
ence between subgroups of trials assessing interferon or
NA (test for subgroup differences, p=0.854). The overall
result was conﬁrmed in sensitivity analyses including
RCTs with a low risk of bias and trials with HCC
screening.
Sensitivity analyses including prospective cohort
studies and case–control studies were performed. In the
cohort studies, HCC was diagnosed in 51 of 436 patients
in the treatment group and 174 of 1853 patients in the
control group. In the case–control studies, the numbers
were 99 of 1778 and 201 of 1827 patients, respectively. A
meta-analysis that combined RCTs and observational
studies found no effect of antiviral therapy on HCC
(relative risk 0.88, 95% CI 0.73 to 1.05; I2=63%). There
was no evidence of small-study effects (Egger’s test,
p=0.730). Subgroup analyses showed a clear difference
between the RCTs, prospective cohorts and case–control
studies (test for subgroup differences, p<0.001; ﬁgure 2).
The prospective cohort studies found that antiviral
therapy increased the risk of HCC (relative risk 1.44,
95% CI 1.06 to 1.95), whereas the case–control studies
found that antiviral therapy reduced the risk of HCC
(relative risk 0.69, 95% CI 0.54 to 0.88). Owing to the
high heterogeneity, a post hoc meta-regression analysis
was performed. We evaluated the study and patient char-
acteristics not accounted for in the sensitivity analyses,
which may have inﬂuenced the result. No modiﬁers
were found when adjusting for the following variables:
proportion of men (coefﬁcient, −0.074; p=0.08), mean
age of treated patients at inclusion (coefﬁcient, 0.020;
p=0.94), mean age of untreated patients at inclusion
(coefﬁcient, 0.121; p=0.65), proportion with cirrhosis at
inclusion (coefﬁcient, −0.001; p=0.76) and region of
trial (coefﬁcient −0.394; p=0.55).
To further evaluate the inﬂuence of bias on the overall
results, we performed additional subgroup analysis in
which trials were stratiﬁed for HCC screening. The analysis
found 8 trials that did not perform HCC screening (rela-
tive risk 0.40, 95% CI 0.26 to 0.63) and 18 trials that did
perform HCC screening (relative risk 1.03, 95% CI 0.84 to
1.25). The results of subgroups were clearly different (test
for subgroup differences, p<0.001).
Sensitivity analyses were performed to evaluate the risk
of HCC among patients with cirrhosis. In the RCTs, 1 of
20 patients in the treatment group and 2 of 12 controls
developed HCC (relative risk 0.75, 95% CI 0.10 to 5.77).
In the prospective cohort studies, 32 of 184 vs 142 of
482 patients developed HCC, whereas the numbers were
63 of 680 vs 161 of 955, respectively, for case–control
studies. Overall, antiviral therapy reduced the risk of
HCC when including data from RCTs and observational
studies (relative risk 0.74, 95% CI 0.57 to 0.96, I2=0%,
number needed to treat 28 patients; ﬁgure 3). The
results of RCTs and observational studies were similar
(test for subgroup differences, p=0.159). There was no
evidence of small-study effects (Egger’s test, p=0.890). In
the trial sequential analysis, the monitoring and
α-spending boundaries did not cross, suggesting that the
result was not robust to adjustment for multiple testing.
Mortality
In the RCTs, there was no difference in mortality
between the treatment and control groups (21 of 508 vs
9 of 271 patients, relative risk 1.24, 95% CI 0.58 to 2.66;
I2=0%). There was no evidence of small-study effects
(Egger’s test, p=0.783) and no difference between trials
stratiﬁed by treatment (test for subgroup differences,
p=0.668) and HCC screening (p=0.828). In the observa-
tional studies, the number of patients in the treatment
and control groups who died was 51 of 655 vs 247 of
2231 for prospective cohort studies and 79 of 506 vs 92
Table 3 Risk of bias summary
Study, year (reference)
Random
sequence
generation
Allocation
concealment
Blinding of
participants
and personnel
Blinding of
outcome
assessment
Incomplete
outcome
data
Selective
reporting
Anderson et al, 198735 ? ? + + ? ?
Chan et al, 200739 + + + + ? ?
Farci et al, 200443 + + + + ? ?
Krogsgaard, 199828 ? ? + + − ?
Liaw et al, 200427 + + + + + +
Mazzella et al, 199953 ? ? + + + ?
Robson et al, 199256 ? ? + + ? ?
Waked et al, 199062 ? ? + + ? ?
+, Low risk of bias; −high risk of bias; ?, unknown risk of bias.
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of 413 in the cohort studies. When combining RCTs and
observational studies, random-effects meta-analysis
showed that antiviral treatment decreased mortality
(relative risk 0.76, 95% CI 0.62 to 0.95, I2=14%, number
needed to treat 77; Egger’s test, p=0.487; ﬁgure 4).
There was no difference between RCTs and observa-
tional studies (test for subgroup differences, p=0.406).
In the trial sequential analysis, the monitoring boundary
crossed the α-spending boundary in 2004, suggesting
that the meta-analysis was robust to adjustments for mul-
tiple testing.
Only observational studies reported mortality in
patients with cirrhosis. The number of patients who died
in the intervention and control groups was 36 of 298 vs
141 of 499 (relative risk 0.61, 95% CI 0.44 to 0.86,
I2=9%; number needed to treat 16 patients). There were
no small-study effects (Egger’s test, p=0.533) and no
differences between the prospective cohort and case–
control studies (test for subgroup differences, p=0.292).
HCC-related mortality
Antiviral therapy had no effect on HCC-related mortality
(3 of 282 vs 2 of 154, relative risk 0.50, 95% CI 0.10 to 2.44,
I2=0%; n=2 RCT). Including data from observational
studies had little inﬂuence on the overall result (38 of
1233 vs 144 of 2632, relative risk 0.83, 95% CI 0.5 to 1.20,
I2=0%; Egger’s test, p=0.248). There was no difference
between subgroups of trials stratiﬁed by design (test for
subgroup differences, p=0.481).
DISCUSSION
This systematic review found that the evidence of the
effect of antiviral therapy on clinical outcomes in HBV is
Figure 2 Random-effects inverse variance meta-analysis of antiviral therapy treatment effects on hepatocellular carcinoma in
patients with chronic hepatitis B, subgroups according to trial design.
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weak. RCTs found no beneﬁt of treatment on HCC,
mortality or HCC-related mortality in HBV. The total
number of patients and duration of follow-up may be
too small to determine the clinical effects. The inclusion
of observational studies did not strengthen the overall
ﬁndings because there was clear evidence of bias sug-
gesting that the study design was closely related to the
estimated treatment effects. The prospective cohort
studies found that antiviral therapy increased the risk of
HCC and had no effect on mortality. Case–control
studies found that antiviral therapy reduced HCC and
mortality. These ﬁndings suggest that detection and
ascertainment bias as well as confounding by indication
had a considerable inﬂuence on the overall result,
which may explain why previous meta-analyses have dis-
agreed in their assessment of the beneﬁt of antiviral
therapy.16–18 20 21 23 24 The importance of detection bias
was underlined in the subgroup analysis of HCC screen-
ing. No intervention effect was found in trials that per-
formed systematic HCC screening.
The main limitation of our review is the limited number
of RCTs. Only one of the included trials had prevention of
HCC as a primary outcome measure27 and none were
designed to evaluate the effect on mortality or HCC-related
mortality. Tests to evaluate the robustness of the results
(including Egger’s test) were difﬁcult to interpret.
The current recommendation to treat patients with
HBV is primarily based on surrogate outcomes. At
present, the evidence supporting the use of virological
markers as surrogate outcomes is weak. The fact that
some studies have found a correlation between a viro-
logical response and improved liver histology does not
necessarily validate their use as surrogate outcomes.
Previous evidence has shown that interventions sup-
ported by surrogate markers may in fact have no beneﬁt
or even harmful effects on clinical outcome measures.68
Still, our ﬁndings are not sufﬁciently convincing and do
not allow for changes in clinical practice.
Another limitation of the current review is our failure
to extract data for analyses of treatment responders
versus non-responders. However, only six cases of HCC
were reportedly diagnosed in patients with biochemical
or viral treatment response. This suggests that treatment
response does not lead to elimination of the HCC risk,
Figure 3 Random-effects inverse variance meta-analysis of antiviral therapy treatment effects on hepatocellular carcinoma
in patients with chronic hepatitis B and cirrhosis, subgroups according to trial design.
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but probably decreases HCC incidence compared to
non-responders or partial responders. This would be in
line with previous ﬁndings.19 25 The majority of included
trials in the current review assessed ﬁrst-generation NA
and interferon, as reﬂected by the low response rates.
It was, however, not within the scope of the review to
investigate modern antiviral treatments, as we included
untreated control groups. Newer treatments will most
likely result in more patients achieving sustained sup-
pression of HBV–DNA. It is therefore possible that the
current review underestimates a potential treatment
effect. It would also have been of interest had we been
able to adjust for other common risk factors for HCC,
such as non-alcoholic steatohepatitis, alcoholic liver
disease and coinfection with hepatitis C virus (HCV),
hepatitis D and HIV. Although data on these risk factors
were extracted, there was not enough data to allow for
statistical analyses.
There are several potential explanations for the dis-
crepancies between RCTs and observational studies.69
The fact that only prospective cohort studies found an
increased risk of HCC among patients receiving antiviral
therapy is in opposition to speculations that the treat-
ment affected HCC development. The ﬁndings are
more likely to reﬂect baseline differences in the viral
load, genotype and degree of liver disease. The degree
of monitoring in the treatment and control groups is
also likely to differ and may lead to detection bias. The
importance of detection bias is further supported by the
subgroup differences observed according to HCC
screening. The case–control studies are likely to have an
even higher risk of bias, as confounding by indication
and ascertainment bias is likely to exist in retrospective
studies. Reporting bias should also be considered.33
The subgroup differences with regard to the type of
intervention suggest a possible anticarcinogenic effect of
interferon, as seen in HCV.70 We also found a decrease
in HCC incidence and overall mortality in sensitivity ana-
lyses of patients with cirrhosis. This could support the
case for continued treatment of patients with cirrhosis.
Figure 4 Random-effects inverse variance meta-analysis of antiviral therapy treatment effects on mortality in patients with
chronic hepatitis B, subgroups according to trial design.
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We found a beneﬁcial effect of interferon and/or NA
on mortality in HBV when including RCTs and observa-
tional studies. The assessment of mortality is robust to
bias.71 Accordingly, our subgroup analysis showed no
clear relation between the results and the study design.
HCC mortality is more prone to bias. Whether antiviral
treatment for HBV decreases mortality except from
HCC is unknown.
In conclusion, antiviral treatment for HBV has no
proven effect on the clinical outcomes, HCC and mortal-
ity. Bias has a paramount impact on the treatment effect
estimates in observational studies and we recommend a
critical approach to the conclusions drawn in such
studies. Future trials on antiviral treatment for HBV
should be designed to show an effect on clinical end-
points rather than surrogate markers.
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